Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

• ClinicalTrials.gov Identifier: NCT03063619
• Recruitment Status: Active, not recruiting
• First Posted: February 24, 2017
• Last Update Posted: April 26, 2023
• Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): M.D. Anderson Cancer Center

Study Description

Brief Summary:

This randomized phase II trial studies how well afimoxifene works in reducing the risk of breast cancer in women with mammographically dense breast. Estrogen can cause the growth of breast cancer cells. Hormone therapy using afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.

Condition or disease	Intervention/treatment	Phase
Mammographically Dense Breast	Drug: Afimoxifene; Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Questionnaire Administration	Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To estimate and compare the percent change in mammographic breast density (using Cumulus software) from baseline to month 12 in women applying 4mg afimoxifene (4-hydroxytamoxifen [4-OHT]) gel per breast versus placebo.

SECONDARY OBJECTIVES:

I. To compare the Cumulus versus (vs.) Volpara breast density measurement methods to estimate percent change in mammographic breast density from baseline to month 12 in women applying 4mg of 4-OHT gel per breast vs. placebo.

II. To compare the percentage of women who underwent a change in Breast Imaging Reporting and Data System (BIRADS) category, comparing pre-and post- treatment measurements, for recipients of active agent versus placebo.

III. To estimate percentage of women with >= 10% absolute decrease in quantitative mammographic density percentage between baseline and 12 months, comparing between treated group 4mg per breast 4-OHT gel to placebo.

IV. To describe symptoms assessed by breast cancer prevention trial (BCPT) eight symptom scale (BESS) questionnaire and laboratory toxicity assessment (factor VIII [F VIII], Von Willebrand [vWB] factor, sex hormone-binding globulin [SHBG], lipid profile).

V. To evaluate serum measurements of 4-OHT and related metabolite levels and factors related to tamoxifen exposures, such as insulin-like growth factor (IGF) pathway members, C-reactive protein (CRP), estradiol.

VI. To evaluate tissue biomarkers (among women undergoing optional pre- and post-treatment biopsies): terminal duct lobular unit (TDLU) involution; collagen structural changes; SETER/PR index: estrogen related transcription, Ki-67, COX-2, p16, CD68.

VII. To examine whether any reductions in mammographic density seen after 1 year of 4-OHT vs. placebo gel application persist at 24 months, one year after gel application has stopped.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM A: Patients apply placebo gel topically to each breast once daily (QD) for up to 52 weeks.

ARM B: Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.

After completion of study treatment, patients are followed up at 24 months.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 194 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Prevention
• Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast
• Actual Study Start Date: May 1, 2017
• Estimated Primary Completion Date: October 26, 2023
• Estimated Study Completion Date: October 26, 2023

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Arm A (placebo); Patients apply placebo gel topically to each breast QD for up to 52 weeks.	Other: Laboratory Biomarker Analysis; Correlative studies; Other: Placebo; Applied topically; Other Names: placebo therapy; PLCB; sham therapy; Other: Questionnaire Administration; Ancillary studies
Experimental: Arm B (afimoxifene); Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.	Drug: Afimoxifene; Applied topically; Other Names: 4-Hydroxy-Tamoxifen; 4-Hydroxytamoxifen; 4-OHT; Other: Laboratory Biomarker Analysis; Correlative studies; Other: Questionnaire Administration; Ancillary studies

Outcome Measures

Primary Outcome Measures :

1. Percent change in mammographic density (MD) (using Cumulus software) in women applying 4mg 4-OHT gel per breast versus placebo [ Time Frame: Baseline up to 12 months ]
   Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for each arm. The difference of the change in percent MD will be compared between two groups using t-test or Wilcoxon rank sum test, when appropriate. Transformation may be performed when necessary to make the measure of MD close to normal distribution before evaluating the change of MD over time between two groups using repeated measures analysis where the intra-patient correlation is taken into consideration, adjusting for other important covariates.

Secondary Outcome Measures :

1. Automatic software breast density measurement methods to estimate percent change in mammographic breast density [ Time Frame: Baseline up to 12 months ]
   Compared to cumulus method in women applying 4mg of 4-OHT gel per breast vs. placebo.
2. Breast tissue density [ Time Frame: Up to 12 months ]
   Evaluated by assessing the patterns of collagen matrix. Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of these continuous variables over time between two groups using r
3. Hormone-mediated cellular activity [ Time Frame: Up to 12 months ]
   Evaluated by measuring the transcriptional expression levels of ER-alpha and ER-associated genes (SETER/PR index). Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of thes
4. Inflammatory response to 4-OHT therapy [ Time Frame: Up to 12 months ]
   Evaluated by measuring COX2 and p16 proteins, and recruitment of CD68 monocytes by immunohistochemistry. Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of these continuo
5. Markers of tamoxifen exposure [ Time Frame: Baseline up to 12 months ]
   Serum measurements of 4-OHT and related metabolite levels and factors related to tamoxifen exposures, such as IGF pathway members, CRP, estradiol, and 4-OHT will be measured. Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close
6. Markers of Toxicity assessed using BESS questionnaire [ Time Frame: Baseline up to 12 months ]
   Blood based toxicity markers will be also evaluated (F VIII, vWB factor, SHBG, lipid profile). Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of these continuous varia
7. Percentage of women who underwent a change in BIRADS category [ Time Frame: Baseline up to 12 months ]
8. Percentage of women with >= 10% absolute decrease in quantitative mammographic density percentage [ Time Frame: Baseline up to 12 months ]
   Compared between treated group 4mg per breast 4-OHT gel versus placebo. Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of these continuous variables over time between t
9. Pharmacogenomic response to 4-OHT [ Time Frame: Up to 12 months ]
   Evaluated by measuring Ki67 protein by immunohistochemistry and aurora kinase-alpha gene expression. Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of these continuous v
10. Reductions in mammographic density after 1 year of 4-OHT vs. placebo gel application [ Time Frame: 24 months ]
    The change in percent MD of the breast from the end of the treatment at 1 year to 1 year after the treatment ends will also be summarized using descriptive statistics, such as mean, standard deviation, median and range for each arm. The difference of this change in percent MD will be compared between two treatment groups using t-test or Wilcoxon rank sum test, when appropriate.
11. Structure-function activity of TLDUs [ Time Frame: Up to 12 months ]
    Evaluated by counting acinar density. Will be summarized using descriptive statistics, such as mean, standard deviation, median and range for continuous variables and frequency/percentage for discrete variables. The difference of continuous variables between baseline and 52 weeks may be compared between two groups using t-test or Wilcoxon rank sum test, whichever is appropriate. Transformation may be performed when necessary to make continuous variables close to normal distribution before evaluating the change of these continuous variables over time between two groups using repeated measures a

Eligibility Criteria

• Ages Eligible for Study: 40 Years to 69 Years (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Women age 40-69 years, or less than 40 years if 5-year breast cancer Gail risk is ≥ 1.66%.
• Mammographically dense breast (heterogeneously dense [C] or extremely dense [D], based on American College of Radiology [ACR] BIRADS fifth edition classification or heterogeneously dense [3] or extremely dense [4], based on ACR BIRADS fourth edition classification) in either breast
• Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)
• White blood cells >= 3,000/microliter
• Absolute neutrophil count >= 1,500/microliter
• Platelets >= 100,000/microliter
• Total bilirubin within normal institutional limits
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 × institutional upper limit of normal (ULN)
• Creatinine within normal institutional limits
• Participant must have a gynecology examination within the last 3 years, with no atypical hyperplasia and no cancer
• Premenopausal women taking non hormonal intra-uterine device (IUD) birth control method will be eligible, if they have been on the same IUD for at least 3 months prior to enrollment and plan to continue using the same method throughout the study
• Women of child-bearing potential must agree to use a reliable nonhormonal contraceptive method during the study and for 2 months after completing study medications; reliable nonhormonal methods of contraception include barrier contraception and an intra-uterine device (IUD); Note: women who had tubal ligation or had a partner who had undergone a vasectomy (and are monogamous) are eligible for the study and are not required to use barrier contraception
• If the participant is of childbearing potential, she must have a documented negative urine pregnancy test within 7 days prior to randomization
• Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to 4-OHT gel
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thromboembolic disease, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant, or had given birth, or nursed at any time during the last 12 months
• Women with a previous history of invasive breast cancer or bilateral ductal carcinoma in situ (DCIS) or current untreated DCIS; women with a history of cancer within the last 3 years, except for non-melanoma skin cancer; women with unilateral DCIS (with or without radiation therapy) are eligible as long as they have an unaffected breast
• Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions)
• Women with "mosaic mammographic screening views", i.e., whose larger breast size precludes being imaged within a single mammographic screening view
• Women with active liver disease, abnormal uterine bleeding, or prior diagnosis of endometrial hyperplasia
• Prior use of selective estrogen receptor modulators (SERMS) and aromatase inhibitors (AIs) for prevention or therapy
• Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration)
• Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study

Contacts and Locations

Locations

United States, Florida

Moffitt Cancer Center

Tampa, Florida, United States, 33612

United States, Illinois

Northwestern University

Chicago, Illinois, United States, 60611

United States, Massachusetts

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

United States, New York

Columbia University/Herbert Irving Cancer Center

New York, New York, United States, 10032

United States, Texas

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

National Cancer Institute (NCI)

Investigators

• Principal Investigator: Banu Arun, MD; M.D. Anderson Cancer Center

More Information

Additional Information:

M D Anderson Cancer Center 

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT03063619
• Other Study ID Numbers: 2017-0328; NCI-2017-00244 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); N01-CN-2012-00034 ( CTRP (Clinical Trial Reporting Program) ); 2017-0328 ( Other Identifier: MD Anderson Cancer Center ); MDA2016-07-02 ( Other Identifier: DCP ); N01CN00034 ( U.S. NIH Grant/Contract )
• First Posted: February 24, 2017
• Last Update Posted: April 26, 2023
• Last Verified: April 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Tamoxifen; Afimoxifene; Estrogen Antagonists; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal; Antineoplastic Agents; Selective Estrogen Receptor Modulators; Estrogen Receptor Modulators; Bone Density Conservation Agents